116 Chapter 6 (Figure 3A). The majority of respondents from all continents except Oceania (48%) indicated that they would use oral switch therapy in uncomplicated SAB (57%–71%). Over half (54%–66%) of respondents from every continent identified patients with SAB originating from skin or soft tissue infection as a suitable patient group for safe oral switch therapy. By contrast, respondents differed widely on their views of the acceptability of oral therapy for SAB associated with spondylodiscitis, ranging from 19% in Africa to 60% in Oceania (Table 1). Source control and absence of a central nervous system infection were the only criteria for oral switch therapy for which there was broad agreement among respondents (79% and 69%, respectively) (Supplementary Table 1). Figure 1. Global distribution of survey respondents. Respondents per country: 71 unique countries participated, and participation ranged from 1 to 654 respondents per country.
RkJQdWJsaXNoZXIy MTk4NDMw